GRFS - Grifols jumps on report on takeover speculation (update)

Update 1:25pm: Updates shares, adds Grifols no comment. Grifols SA (NASDAQ:GRFS) advanced 13% on speculation that the pharmaceuticals and chemicals maker has seen some takeover interest. There's some speculation that some private equity firms are looking at Grifols (GRFS), according to a Betaville "uncooked" alert. One PE firm is said to be in the U.S, while one is in London. Not clear if the buyout firms have approached GRFS with a takeover offer. Grifols told Seeking Alpha in an email that it doesn't comment on rumors or speculation. Grifols (GRFS), which has a market cap of about $10 billion, agreed to acquire Biotest AG, a German public listed company focused on plasma-derived products, for about $2 billion in September. Earlier this month, Grifols ABvac40 vaccine for Alzheimer's showed safety/response in phase 2 interim data.

For further details see:

Grifols jumps on report on takeover speculation (update)